Analysts made no major changes to their price target of AU$2.44, suggesting the downgrades are not expected to have a long-term impact on Estia Health's valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Estia Health, with the most bullish analyst valuing it at AU$2.69 and the most bearish at AU$2.15 per share.